Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Mayne Pharma Group ( (AU:MYX) ) has provided an announcement.
Goldman Sachs Group, including its Australian subsidiaries, has notified Mayne Pharma Group that it has ceased to be a substantial shareholder in the company as of 15 January 2026, in line with disclosure requirements under the Corporations Act. The change in holding, formally lodged with the ASX via a substantial shareholder notice, signals that Goldman Sachs’ aggregate voting interest in Mayne Pharma has fallen below the substantial shareholder threshold, potentially altering the company’s institutional investor base and the balance of influence among its major shareholders.
The most recent analyst rating on (AU:MYX) stock is a Sell with a A$2.50 price target. To see the full list of analyst forecasts on Mayne Pharma Group stock, see the AU:MYX Stock Forecast page.
More about Mayne Pharma Group
Mayne Pharma Group Limited is an Australian pharmaceutical company listed on the ASX that develops, manufactures and markets branded and generic medicines. The company focuses on specialty and generic products, with operations spanning formulation development, manufacturing and distribution for domestic and international markets.
YTD Price Performance: -8.68%
Average Trading Volume: 581,893
Technical Sentiment Signal: Sell
Current Market Cap: A$230.7M
For an in-depth examination of MYX stock, go to TipRanks’ Overview page.